NASDAQ$EQ
Equillium Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2022 and provided an update on its clinical development programs.
Equillium reported a net loss of $13.7 million for Q3 2022. The company announced a pending acquisition of Metacrine, expected to add $35 million in cash and extend operating runway into 2024. They also initiated Phase 2 study of EQ101 and Phase 1 study of EQ102.
- Announced positive interim results from the EQUALISE study of itolizumab in highly proteinuric lupus nephritis patients.
- Announced the pending acquisition of Metacrine, expected to add $35 million in cash at closing and extend operating runway into 2024.
- Initiated Phase 2 study of EQ101 in alopecia areata and Phase 1 study of EQ102 in healthy volunteers and celiac disease patients.
- R&D expenses increased to $8.8 million, and G&A expenses increased to $4.5 million.
Headline financials
Revenue & EPS history
Equillium · Revenue · Quarterly
$0
Forward guidance
Equillium anticipates several milestones and catalysts in the near future.
Tailwinds
- Topline data from the Type B part of the itolizumab EQUALISE Phase 1b study in patients with lupus nephritis expected mid-2023.
- Data from the EQ101 Phase 2 study in subjects with alopecia areata expected in 2023.
- Data from the EQ102 Phase 1 study in healthy volunteers and subjects with celiac disease expected in 2023.
- The Metacrine acquisition will add approximately $35 million to the balance sheet.
- The Metacrine acquisition will extend the company's cash runway into 2024.
Headwinds
- There are no guarantees that any of Equillium's ongoing or planned clinical studies will show safety or efficacy.
- Delays in the commencement, enrollment, and completion of clinical studies and the reporting of data therefrom are possible.
- Studies may not be completed as planned.
- Changes in the competitive landscape could negatively impact Equillium.
- Market volatility may impact cash reserves.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+1.0%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-1.3%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+42.0%
Q3 2020
Best reaction
-27.0%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.8% | -18.9% | — | |
| Q3 2025 | +23.8% | +20.2% | +52.4% | |
| Q2 2025 | +16.3% | +16.3% | +90.8% | |
| Q1 2025 | +5.4% | +5.4% | -5.4% | |
| Q1 2026 | +5.4% | +5.4% | -5.4% | |
| Q4 2024 | -2.5% | -10.0% | -16.0% | |
| Q3 2024 | -19.5% | -20.0% | -17.6% | |
| Q2 2024 | -4.6% | +0.0% | +27.4% | |
| Q1 2024 | -10.0% | -9.4% | -52.9% | |
| Q4 2023 | -27.0% | -18.1% | -36.5% | |
| Q3 2023 | -1.8% | +0.0% | +22.0% | |
| Q2 2023 | +3.9% | +2.6% | +6.5% | |
| Q1 2023 | +3.6% | +7.1% | +17.9% | |
| Q4 2022 | +12.3% | +10.8% | -4.6% | |
| Q3 2022 | +6.5% | +5.9% | -28.2% | |
| Q2 2022 | +1.4% | -1.8% | -25.5% | |
| Q1 2022 | +3.7% | +13.8% | +0.0% | |
| Q4 2021 | +0.0% | -9.1% | -10.3% | |
| Q3 2021 | -13.6% | -14.5% | -27.0% | |
| Q2 2021 | +2.7% | +2.2% | -2.4% | |
| Q1 2021 | +6.1% | +22.3% | +19.0% | |
| Q4 2020 | -8.5% | -12.7% | -19.5% | |
| Q3 2020 | +42.0% | +27.6% | +34.1% | |
| Q2 2020 | -12.8% | -29.7% | -45.0% | |
| Q1 2020 | -14.9% | -20.6% | -19.7% | |
| Q4 2019 | -1.1% | +2.3% | +7.5% | |
| Q3 2019 | -1.2% | +7.1% | +45.7% | |
| Q2 2019 | -0.5% | +7.1% | -0.5% | |
| Q1 2019 | +2.0% | +2.5% | +0.3% | |
| Q4 2018 | +6.1% | +9.2% | -20.2% | |
| Q3 2018 | +6.4% | -8.7% | -24.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro